about
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoExpression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patientsIdentification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasmaNovel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor geneElevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis.TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimensDevelopment of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.Improving selection criteria for lung cancer screening. The potential role of emphysema.A gene-alteration profile of human lung cancer cell lines.Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.The role of complement in tumor growthAssessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histologyEventPointer: an effective identification of alternative splicing events using junction arrays.Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathwayCombined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterationsAnaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.Alternative splicing: an emerging topic in molecular and clinical oncology.Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patientsTGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinomaContrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtypeComplement inhibition in cancer therapy.SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays.Strategies to design clinical studies to identify predictive biomarkers in cancer research.Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.Innate immune mediators in cancer: between defense and resistance.Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.Multiscale in situ analysis of the role of dyskerin in lung cancer cells.Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
P50
Q21245712-130793F1-00D5-4462-81A6-CC62BF700BFFQ27308972-51C181BD-D1BA-4FDC-9EB3-38BAFC67D3D8Q28211285-E4AA9DD9-A6B4-4DD5-B89E-D9C9E93281F5Q28250528-39A9F8A3-C8BE-417D-AAF3-97D2E8790097Q30316699-A0C8C2AA-BBBA-4001-AC2E-6A241079F5EAQ30445142-C7B7C5D9-3D0B-4260-8FD4-589BC6540CEDQ30833632-EC3A7596-0CC2-4ABF-A4D1-0014702F6D16Q33384993-66938FEE-2373-4A0F-ABD0-EFCFD4F8DC63Q33594999-FDCDABBD-75A2-4004-B581-2CFB87C94EA0Q33735712-C790F7E4-5A10-4C81-B89A-A1F01CAE3583Q33978771-78DA7587-8249-4911-9080-FFBD40F01628Q34372539-65A0DDE3-15AA-4768-B7B7-E7AE1821B380Q34663701-6D100738-4D80-4014-BCEC-6BB928ED9964Q35231345-271C1813-34ED-4D6E-97E0-AEFC0EA49CB4Q35584933-96D84CE9-E8A0-4494-8017-9F29B23FB8E0Q35623105-43CF1DD7-5D1C-45DC-92E3-CA6017304F9AQ36055662-6EF73C60-813F-4ECB-8324-ACB8B9E4F80AQ36088646-BF27183C-43E7-49DE-AE26-E9A5DB98412AQ36127123-0D066C02-58B4-45EE-9772-E883CE1F5599Q36338990-09E02F4E-F372-42AF-B227-E132E10B59AAQ36774636-BB898B51-55DA-4D56-8FA0-ABA72D1B2CC6Q37180356-8B3BB719-31A7-40F0-9997-EF47BB9B229BQ37225665-E01EEB8B-56C8-45DB-82AF-6F3D13BD18E1Q37650665-723E4E43-146C-4B15-81BF-69C9A9BED82CQ37709086-FBA794E4-DAC8-4389-A9D4-5DC0CF1FAAE1Q37710826-59C1A65C-448C-493A-965D-DC1C9B779663Q38109340-1A5A147A-C514-4B44-8AE0-549F871DCE28Q38275881-68D931B0-D94A-4B26-AC6B-85B39A95B011Q38770451-8A46FD6B-13C3-4B05-8923-DFEDA41AB5D1Q38796706-F6CEE99F-6D97-4A3A-8682-EBDEE092E48EQ38991015-6073C4EA-6712-497B-8ED0-62D07496699DQ39039467-7C928297-EF12-49D0-9814-A1BF780318C5Q39227538-83072417-1D3B-451F-82BC-3735925F03E9Q39548723-77922F0C-CD6C-4A27-9E87-A80CD0BD1AB0Q39613701-C0EAD093-7EE0-4975-94C7-7F76A74D5E73Q39843151-7B0C614B-8BE1-461C-A720-71E309904140Q39877444-A0379A77-633B-4C3F-9222-307CADCC45E5Q40124238-0FD2B479-85CB-458C-B7AF-4B66E63603C8Q40143966-E98D3CF0-65D8-4700-BC21-9F5D3B38D87FQ40393934-08C13EC5-6053-4730-AB09-385BB4FE4519
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ruben Pio
@ast
Ruben Pio
@en
Ruben Pio
@es
Ruben Pio
@sl
type
label
Ruben Pio
@ast
Ruben Pio
@en
Ruben Pio
@es
Ruben Pio
@sl
prefLabel
Ruben Pio
@ast
Ruben Pio
@en
Ruben Pio
@es
Ruben Pio
@sl
P1053
F-5353-2017
P106
P21
P31
P3829
P3835
P496
0000-0002-6831-6111